Research programme: receptor-associated protein therapeutics - Horizon Pharma

Drug Profile

Research programme: receptor-associated protein therapeutics - Horizon Pharma

Alternative Names: AmpTide; HepTide; NeuroTrans; RAP peptide; RAP-2s; RAP-NGF conjugates; Receptor-Associated Protein-Nerve Growth Factor conjugates

Latest Information Update: 11 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Raptor Pharmaceuticals Corp
  • Developer Horizon Pharma; Raptor Pharmaceutical Corp
  • Class
  • Mechanism of Action Growth factor receptor modulators; Nerve growth factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hepatocellular carcinoma
  • No development reported Hepatitis C; Mesothelioma; Neurodegenerative disorders

Most Recent Events

  • 12 Aug 2014 HepTide™ is still in preclinical development for Hepatocellular carcinoma in USA
  • 09 May 2013 No development reported - Preclinical for Neurodegenerative disorders in USA (IV)
  • 09 May 2013 HepTide™ is still in preclinical development for Hepatocellular carcinoma in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top